| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 225,178 | 58,085 | ||
| Marketable securities | 118,812 | 122,741 | ||
| Accounts receivable, net | 132 | 103 | ||
| Prepaid expenses and other current assets | 9,261 | 5,961 | ||
| Total current assets | 353,383 | 186,890 | ||
| Property and equipment, net | 399 | 445 | ||
| Restricted cash equivalents | 983 | 1,451 | ||
| Operating lease right-of-use assets | 5,476 | 5,812 | ||
| Other assets | 2,500 | - | ||
| Total assets | 362,741 | 194,598 | ||
| Accounts payable | 5,339 | 3,294 | ||
| Accrued expenses | 19,471 | 17,465 | ||
| Operating lease liabilities, current portion | 981 | 665 | ||
| Total current liabilities | 25,791 | 21,424 | ||
| Operating lease liabilities, net of current portion | 4,954 | 5,297 | ||
| Total liabilities | 30,745 | 26,721 | ||
| Common stock, 0.0001 par value 300,000,000 shares authorized 109,766,382 and 68,629,738 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 11 | 9 | ||
| Additional paid-in capital | 1,049,598 | 851,359 | ||
| Accumulated deficit | -718,428 | -684,042 | ||
| Accumulated other comprehensive income (loss) | 815 | 551 | ||
| Total stockholders' equity | 331,996 | 167,877 | ||
| Total liabilities and stockholders' equity | 362,741 | 194,598 | ||
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)